The latest Investing Matters Podcast episode has just been released with Asif Suria, Founder & Editor of Inside Arbitrage. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.90
Bid: 12.80
Ask: 13.00
Change: 0.00 (0.00%)
Spread: 0.20 (1.562%)
Open: 12.90
High: 12.90
Low: 12.90
Prev. Close: 12.90
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Poolbeg makes promising progress with RSV programme

Wed, 20th Dec 2023 13:54

(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.

The AIM-traded firm said a team of scientific experts had assessed the extensive data collected during the lab-based analysis, prioritising a select group of RSV drug candidates.

It was now actively exploring the most efficient path to advance the prioritised drug candidates to create value.

Poolbeg Pharma said it was confident that the data obtained underscored the potential of its AI-driven programme, bolstering its collaborative endeavours.

The board said global interest in AI-led drug discovery was rising, with major pharmaceutical companies investing significantly.

Poolbeg's RSV AI programme identified drug treatment candidates within a 10-month timeframe.

It said leveraging AI in drug discovery would accelerate timelines, reduce costs, lower risks, and enhance the probability of successfully introducing groundbreaking therapies to patients.

"The positive outputs from this analysis, and the successful prioritisation of our RSV drug candidates, is a testament to the power of our AI-led drug discovery programme," said chief executive officer Jeremy Skillington.

"As we engage in partnering discussions, these results position Poolbeg as a key player in the evolving landscape of AI-driven drug discovery."

At 1224 GMT, shares in Poolbeg Pharma were up 2.43% at 9.27p.

Reporting by Josh White for Sharecast.com.

More News
6 Sep 2022 14:04

IN BRIEF: Poolbeg shares rises on narrowed loss, strong pipeline

Poolbeg Pharma PLC - London-based pharmaceutical company - In the six months ended June 30, narrows its pretax loss to GBP1.7 million from GBP2.3 million loss the year prior. Does not post a revenue figure, unchanged from the previous year. Research & development expenses rise to GBP657,000 from GBP414,000. Notes "significant" progress on POLB 001, its treatment for severe influenza. Expects outputs from its respiratory syncytial virus and influenza artificial intelligence programmes by the end of 2022 and the second quarter of 2023, respectively. Adds it has "strong financial resources available to progress its products and platforms."

Read more
20 Jul 2022 12:04

IN BRIEF: Poolbeg Pharma shares rise as first human trial begins

Poolbeg Pharma PLC - London-based pharmaceutical company - Receives approval to commence its Lipopolysaccharide human clinical trial for POLB 011, a drug that aims to treat severe influenza. The trial will formally start on Friday. It will assess POLB 011 in damping the immune response to lipopolysaccharide, which acts as a surrogate for the hyperinflammatory response associated with severe influenza. Initial results are expected in the final quarter of 2022. Poolbeg says at that point it intends to "rapidly" monetise by out-licensing and/or partnering with pharmaceutical and biotechnology companies for the drug's further development.

Read more
27 Jun 2022 10:47

Poolbeg Pharma AI model of respiratory syncytial virus starts analysis

(Alliance News) - Poolbeg Pharma PLC on Monday said its build and optimisation of an artificial intelligence model of respiratory syncytial virus data is complete.

Read more
27 May 2022 10:43

AIM WINNERS & LOSERS: Premier Miton advances; Advance Energy retreats

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
26 May 2022 16:54

IN BRIEF: Poolbeg Pharma shares soar on US patent grants

Poolbeg Pharma PLC - London-based pharmaceutical company - Wins patent grants from the US Patent & Trademark Office for its POLB 001 and POLB 002 molecules. The former is used to treat influenza, while the latter is an RNA-based immunotherapy for respiratory virus infections. "The company is continuing working with its patent advisors to broaden and expand the POLB 001 and POLB 002 patent families," Poolbeg says.

Read more
26 May 2022 10:51

AIM WINNERS & LOSERS: Poolbeg wins patents; RA swings to loss

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
12 May 2022 15:35

TRADING UPDATES: Secure Trust lending up; Eurocell sales climb

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
27 Apr 2022 20:15

IN BRIEF: Poolbeg hails shareholder confidence as lock-up period ends

Poolbeg Pharma PLC - London-based pharmaceutical company - Confirms proposals have been accepted by distribution in specie shareholders seeking to sell a total of GBP366,000 of Poolbeg shares, representing only 3% of the distribution in specie shares. Says 97% of distribution in specie shareholders have decided to remain invested in Poolbeg following the end of the lock-up period.

Read more
14 Apr 2022 21:36

TRADING UPDATES: Polar Capital assets up; Brooks Macdonald funds fall

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
14 Apr 2022 14:53

Poolbeg granted European patent for antiviral nose spray

(Sharecast News) - Clinical-stage pharmaceutical company Poolbeg Pharma reported on the strengthening of its intellectual property (IP) for its 'POLB 002' asset on Thursday - a first-in-class, intranasally-administered RNA-based immunotherapy for respiratory virus infections.

Read more
13 Apr 2022 19:46

TRADING UPDATES: McKay backs Workspace offer; IOG fixes Blythe fault

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
11 Apr 2022 21:58

TRADING UPDATES: TruFin raises GBP10 million, Afentra preferred bidder

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
11 Apr 2022 10:57

AIM WINNERS & LOSERS: Mothercare misses payment; Argos licence renewed

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
31 Mar 2022 21:07

TRADING UPDATES: SSE's Transmission raises cash; Croda gets UK grant

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
30 Mar 2022 19:25

IN BRIEF: Poolbeg Pharma starts trading on OTCQB Venture Market

Poolbeg Pharma PLC - London-based pharmaceutical company - Shares start trading on the OTCQB Venture Market in the US.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.